Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

Inclusion Criteria: * Participants who are candidates for routine, uncomplicated cataract surgery * Participants who, in the Investigator's opinion, have potential postoperative pinhole Snellen visual acuity (VA) of at least 20/200 in the study eye. * Participants must be willing to wait to undergo cataract surgery on the fellow eye until after the study has been completed. Exclusion Criteria: * Participants who are expected to require concurrent ocular therapy (either eye) with nonsteroidal anti-inflammatory drugs (NSAIDs), mast cell stabilizers, antihistamines, or decongestants. * Participants who are expected to require treatment with any systemic or ocular (either eye) corticosteroids or glucocorticoids. * Participants who are expected to require concurrent ocular therapy with immunosuppressants (eg, Restasis). * Participants who have known hypersensitivity or contraindication to the study drug(s) or their components. * Participants participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.